Angiotensin-converting–enzyme (ACE) inhibitors and angiotensin-receptor blockers are used commonly in clinical practice to treat hypertension and decrease cardiovascular events in high-risk patients.

Although serum potassium monitoring is recommended to reduce the risk of hyperkalemia, only a small percentage of patients taking RAAS inhibitors are monitored. Hyperkalemia diagnosis is often missed ...

Hyperkalemia treatment trends in the ED are varied and inconsistent, depending on potassium levels when patients reach the ED. Although various treatments decreased potassium over 4 hours, only ...

Hyperkalemia is the medical term for high potassium levels. There are often no symptoms of hyperkalemia, but it can be a sign of kidney disease, dehydration, diabetes complications, and many other ...

Diabetic nephropathy is a complication of diabetes that affects the kidneys. Hyperkalemia refers to high levels of potassium in the blood. Damage to the kidneys can result in hyperkalemia. Diabetic ...

Hyperkalemia, defined as a serum potassium concentration above 5.0 mmol/L, is a frequent and potentially life-threatening complication of chronic kidney disease (CKD). As glomerular filtration rate ...

A real-world study finds reduced RAASi-related hyperkalemia risk among at-risk patients initiating SGLT2 inhibitors. Sodium glucose cotransporter 2 inhibitor (SGLT2i) use is associated with lower ...

AccurKardia, Inc., an ECG analytics software company focused on establishing ECG as a broad biomarker, today announced that ...

Serum potassium levels prior to an acute hyperkalemia episode do not predict mortality, but following this episode, progression from normokalemia to hyperkalemia is significantly associated with an ...